TFS HealthScience Standardizes on Veeva Vault Clinical Operations Suite to Accelerate Clinical Development

TFS HealthScience will be the first CRO to have selected Veeva Vault Clinical Operations Suite for end-to-end study management on a single cloud platform.

The European-headquartered global CRO is taking action to further modernize the study operations, adopting the entire suite to drive greater efficiency and speed in trials. TFS HealthScience will now be offering its biopharma customers industry-leading technologies to improve patient safety whilst reducing the financial burden and increasing compliance.

“Veeva Vault Clinical Operations Suite gives us a foundation for further growth as we expand our service offering globally,” said Dr. Bassem Saleh, CEO, TFS HealthScience. “Bringing together study operations streamlines the processes, enabling us to maximize value for sponsors and accelerate the delivery of treatments to patients.”

TFS HealthScience provides strategic tailored solutions to its customers with a focus on driving excellence and innovation to reduce the complexity across study processes. Building on its success with Veeva Vault eTMF to maintain inspection readiness, the company will use Veeva Vault Study Startup to get studies up and running quickly, Veeva Vault CTMS to keep studies on track, and Veeva Vault Payments to simplify payments to global partner sites. With a connected, agile clinical landscape, TFS HealthScience will centralize governance and study oversight to share insights with sponsors easily.

“With Veeva Vault, we now have complete visibility into study progress and deviations to make better-informed decisions and ensure studies meet their objectives,” said Young Shon, CIO, TFS HealthScience. “Our partnership with Veeva is instrumental to TFS’s digital transformation program and our strategic push towards paperless and patient-centric approaches.”

TFS HealthScience is transforming clinical operations to work more efficiently and better serve sponsors,” said Pinar Benet, senior director strategy, Vault Clinical Operations at Veeva Systems. “We’re excited to continue this journey together towards unified and connected trials to accelerate clinical research.”

Veeva Vault Clinical Operations Suite enables sponsors and CROs to seamlessly share information and documents across CTMS, eTMF, study start-up, and payments for better collaboration and increased efficiency throughout the study lifecycle.

The Veeva Unified Clinical Operations Survey: Annual CRO Report shows that CROs like TFS HealthScience is moving to streamline trial execution by embracing new digital strategies and technologies that eliminate data silos and manual processes. Learn how CROs are modernizing clinical operations to speed trials in the full report, available here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version